Neurocrine Biosciences | NBIX - Equity Capital And Reserves


Neurocrine Biosciences reported $3B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -2.64B 2.46B Sep/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Dynavax Technologies USD 534.14M 39.98M Sep/2025
Exelixis USD 2.16B 127.16M Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Prothena USD 294.99M 29.34M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Repligen USD 442.96M 1.62B Sep/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025